Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 3/20 | 0.53 |
| ▸ | FES | P07332 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.45 |
| ▸ | PRKACA | P17612 | 7/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.44 |
| ▸ | GSK3A | P49840 | 7/20 | 0.44 |
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.44 |
| ▸ | CDC42BPA | Q5VT25 | 7/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.44 |
| ▸ | CSNK1G3 | Q9Y6M4 | 7/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.44 |
| ▸ | PRKG1 | Q13976 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029781 | 0.89 | FLT4 (0.62) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4025437 | 0.89 | FLT4 (0.62) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4026908 | 0.86 | HDAC1 (0.48) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL5753737 | 0.84 | PRKACA (0.56) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4024696 | 0.82 | PRKACA (0.58) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4023026 | 0.82 | PRKACA (0.58) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4024280 | 0.82 | PRKACA (0.58) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4026381 | 0.82 | PRKACA (0.58) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4026892 | 0.82 | PRKACA (0.58) | FLT4FESFGFR1KDRMAPKAPK2 | |
| SCHEMBL4023733 | 0.82 | PRKACA (0.58) | FLT4FESFGFR1KDRMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | claimed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | claimed |
| EP-1674457-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2096107-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| EP-1674457-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | SQLE, FDFT1, DLD | FLT4 3467/4885FES 4525/4885FGFR1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.